Literature DB >> 16545544

Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia.

Shahin Akhondzadeh1, Farzin Rezaei, Bagher Larijani, Ali-Akbar Nejatisafa, Ladan Kashani, Seyed Hesameddin Abbasi.   

Abstract

The aim of this study was to evaluate the relationship between plasma levels of testosterone, FSH, LH and prolactin and the severity of negative symptoms in patients with chronic schizophrenia. Fifty-four male inpatients with chronic schizophrenia participated in this cross-sectional study. Twenty-five age-matched men without a history of psychiatric disorders or endocrine illnesses were used as controls. All patients were on risperidone 4 mg/day or haloperidol 10 mg/day and anticholinegic medication, biperidine 3 mg/day. The patients were assigned to groups with predominant negative and nonpredominant negative symptoms on the basis of their scores on the Positive and Negative Syndrome Scale (PANSS). Plasma levels of testosterone and free testosterone in the patients with predominant and nonpredominant negative symptoms were significantly lower than those in normal controls. Furthermore, plasma levels of FSH and LH, in the patients with predominant negative symptoms but not in the nonpredominant negative symptoms, were significantly lower than those in the normal controls. In contrast, plasma level of prolactin in the predominant negative symptoms group but not in the nonpredominant negative symptoms group was significantly higher than the aged matched normal males. Significant inverse correlation between negative subscale scores of PANSS and plasma levels of testosterone and free testosterone in the patients with predominant negative symptoms were detected. There was also a positive correlation between prolactin plasma levels and negative subscale scores. The present study indicates that assessment of sex hormones and function of hypothalamic-pituitary-gonadotropin axis could be an important biological marker for the severity of negative symptoms in schizophrenia and these findings may change the present pharmacotherapy for negative symptoms based on neuroendocrinology profiles of patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545544     DOI: 10.1016/j.schres.2006.02.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  34 in total

1.  Testosterone in newly diagnosed, antipsychotic-naive men with nonaffective psychosis: a test of the accelerated aging hypothesis.

Authors:  Emilio Fernandez-Egea; Clemente García-Rizo; Brian Miller; Eduard Parellada; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychosom Med       Date:  2011-09-23       Impact factor: 4.312

2.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

3.  A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.

Authors:  Mohammad Arbabi; Mohaddeseh Bagheri; Farzin Rezaei; Seyyed-Ali Ahmadi-Abhari; Mina Tabrizi; Farahnaz Khalighi-Sigaroudi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

Review 4.  Effects of Sex Steroids in the Human Brain.

Authors:  Tuong-Vi Nguyen; Simon Ducharme; Sherif Karama
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

Review 5.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

6.  Genome-Wide Association Study of Psychosis Proneness in the Finnish Population.

Authors:  Alfredo Ortega-Alonso; Jesper Ekelund; Antti-Pekka Sarin; Jouko Miettunen; Juha Veijola; Marjo-Riitta Järvelin; William Hennah
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

Review 7.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

8.  Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.

Authors:  Imran B Chaudhry; Nusrat Husain; Richard Drake; Graham Dunn; M Omair Husain; Ajmal Kazmi; Munir M Hamirani; Raza Rahman; John Stirling; William Deakin
Journal:  Ther Adv Psychopharmacol       Date:  2014-06

9.  Region and sex differences in constituent dopamine neurons and immunoreactivity for intracellular estrogen and androgen receptors in mesocortical projections in rats.

Authors:  Mary F Kritzer; Lela M Creutz
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

10.  In vitro binding assays using (3)H nisoxetine and (3)H WIN 35,428 reveal selective effects of gonadectomy and hormone replacement in adult male rats on norepinephrine but not dopamine transporter sites in the cerebral cortex.

Authors:  B Meyers; M F Kritzer
Journal:  Neuroscience       Date:  2008-12-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.